此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项HMPL-760联合R-GemOx对比安慰剂联合R-GemOx治疗复发/难治性DLBCL的III期研究

2026年11月9日 更新者:Hutchmed

一项评估HMPL-760联合R-GemOx对比安慰剂联合R-GemOx在复发/难治性弥漫性大B细胞淋巴瘤(DLBCL)患者中的疗效、安全性和药代动力学的III期随机、双盲、阳性对照研究

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

研究概览

详细说明

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

研究类型

介入性

注册 (估计的)

240

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Baoding、中国
        • 招聘中
        • Baoding NO.1 Central Hospital
        • 接触:
        • 首席研究员:
          • Haiying Yao
      • Beijing、中国
        • 招聘中
        • Beijing GoBroad Hospital
        • 首席研究员:
          • Kai Hu
        • 接触:
      • Beijing、中国
        • 招聘中
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • 首席研究员:
          • Liang Wang
        • 接触:
      • Bengbu、中国
        • 招聘中
        • The First Affiliated Hospital of Bengbu Medical College
        • 接触:
        • 首席研究员:
          • Yanli Yang
      • Changchun、中国
        • 招聘中
        • The First Hospital of Jilin University
        • 首席研究员:
          • Ou Bai
        • 接触:
      • Changsha、中国
        • 招聘中
        • Hunan Cancer Hospital
        • 首席研究员:
          • Hui Zhou
        • 接触:
      • Changsha、中国
        • 招聘中
        • The Second Xiangya Hospital of Central South University
        • 首席研究员:
          • Hongling Peng
        • 接触:
      • Changsha、中国
        • 招聘中
        • People's Hospital of Hunan Province
        • 接触:
        • 首席研究员:
          • Can Liu
      • Chengdu、中国
        • 招聘中
        • West China Hospital of Sichuan University
        • 首席研究员:
          • Liqun Zou
        • 接触:
      • Chengdu、中国
        • 招聘中
        • Sichuan Provincial People's Hospital
        • 接触:
        • 首席研究员:
          • Xiaobing Huang
      • Chongqing、中国
        • 招聘中
        • The First Affiliated Hospital of Chongqing Medical University
        • 首席研究员:
          • Xin Wang
        • 接触:
      • Chongqing、中国
        • 招聘中
        • Chongqing University Cancer Hospital
        • 首席研究员:
          • Yao Liu
        • 接触:
      • Fujian、中国
        • 招聘中
        • Quanzhou First Hospital.Fujian
        • 接触:
        • 首席研究员:
          • Xiongpeng Zhu
      • Fuzhou、中国
        • 招聘中
        • Fujian Medical University Union Hospital
        • 首席研究员:
          • Jianzhen Shen
        • 接触:
      • Guangzhou、中国
        • 招聘中
        • Sun Yat-sen University Cancer Center
        • 首席研究员:
          • Zhiming Li
        • 接触:
      • Guangzhou、中国
        • 招聘中
        • Guangdong Provincial People's Hospital
        • 接触:
        • 首席研究员:
          • Xiaojuan Wei
      • Guangzhou、中国
        • 招聘中
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • 首席研究员:
          • Yuhua Li
        • 接触:
      • Guiyang、中国
        • 招聘中
        • The Affiliated Hospital of Guizhou Medical University
        • 首席研究员:
          • Yan Zhang
        • 接触:
      • Hangzhou、中国
        • 招聘中
        • Zhejiang Cancer Hospital
        • 首席研究员:
          • Haiyan Yang
        • 接触:
      • Hangzhou、中国
        • 招聘中
        • The First Affiliated Hospital, Zhejiang University
        • 首席研究员:
          • Zhen Cai
        • 接触:
      • Harbin、中国
        • 招聘中
        • Harbin Medical University Cancer Hospital
        • 接触:
        • 首席研究员:
          • Qingyuan Zhang
      • Hefei、中国
        • 招聘中
        • The Second Affiliated Hospital of Anhui Medical University
        • 接触:
        • 首席研究员:
          • Zhimin Zhai
      • Jinan、中国
        • 招聘中
        • Qilu Hospital of Shandong University
        • 接触:
        • 首席研究员:
          • Shuqian Xu
      • Jinan、中国
        • 招聘中
        • Shandong Cancer Hospital & Institute
        • 首席研究员:
          • Zengjun Li
        • 接触:
      • Kunming、中国
        • 尚未招聘
        • The First Affiliated Hospital of Kunming Medical University
        • 接触:
        • 首席研究员:
          • Mingxia Shi
      • Nanchang、中国
        • 招聘中
        • Jiangxi Cancer Hospital
        • 首席研究员:
          • Yan Huang
        • 接触:
      • Nanjing、中国
        • 招聘中
        • Jiangsu Cancer Hospital
        • 首席研究员:
          • Yan Zhang
        • 接触:
      • Nanjing、中国
        • 招聘中
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • 接触:
        • 首席研究员:
          • Jingyan Xu
      • Nanning、中国
        • 招聘中
        • The First Affiliated Hospital of Guangxi Medical University
        • 首席研究员:
          • Zhigang Peng
        • 接触:
      • Qingdao、中国
        • 招聘中
        • The Affiliated Hospital of Qingdao University
        • 接触:
        • 首席研究员:
          • Xia Zhao
      • Shanghai、中国
        • 招聘中
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • 首席研究员:
          • Weili Zhao
        • 接触:
      • Shanghai、中国
        • 招聘中
        • Tongji Hospital of Tongji University
        • 接触:
        • 首席研究员:
          • Ping Li
      • Shanghai、中国
        • 尚未招聘
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • 首席研究员:
          • Ligen Liu
        • 接触:
      • Shenyang、中国
        • 招聘中
        • Shengjing Hospital of China Medical University
        • 首席研究员:
          • Wei Yang
        • 接触:
      • Shenzhen、中国
        • 招聘中
        • Shenzhen people's hospital
        • 首席研究员:
          • Jihao Zhou
        • 接触:
      • Taiyuan、中国
        • 招聘中
        • Shanxi Provincial Cancer Hospital
        • 首席研究员:
          • Liping Su
        • 接触:
      • Tangshan、中国
        • 招聘中
        • North China University of Science and Technology Affiliated Hospital
        • 接触:
        • 首席研究员:
          • Zhenyu Yan
      • Tianjin、中国
        • 招聘中
        • Tianjin Medical University Cancer Institute & Hospital
        • 首席研究员:
          • Zhengzi Qian
        • 接触:
          • Zhengzi Qian
          • 电话号码:13702031222
          • 邮箱:qzz@163.com
      • Tianjin、中国
        • 招聘中
        • Tianjin People's Hospital
        • 接触:
        • 首席研究员:
          • Xingli Zhao
      • Tianjin、中国
        • 招聘中
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • 首席研究员:
          • Dehui Zou
        • 接触:
      • Wenzhou、中国
        • 招聘中
        • The First Affiliated Hospital of WMU
        • 接触:
        • 首席研究员:
          • Songfu Jiang
      • Wuhan、中国
        • 招聘中
        • Hubei Cancer Hospital
        • 首席研究员:
          • Huijing Wu
        • 接触:
      • Wuhan、中国
        • 招聘中
        • Wuhan Union Hospital of China
        • 首席研究员:
          • Liling Zhang
        • 接触:
      • Xi'an、中国
        • 招聘中
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • 首席研究员:
          • Pengcheng He
        • 接触:
      • Xi'an、中国
        • 招聘中
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • 首席研究员:
          • Jie Liu
        • 接触:
      • Xiamen、中国
        • 尚未招聘
        • The First Affiliated Hospital of Xiamen University
        • 首席研究员:
          • Bing Xu
        • 接触:
      • Xuzhou、中国
        • 招聘中
        • The Affiliated Hospital of Xuzhou Medical University
        • 接触:
        • 首席研究员:
          • Wei Sang
      • Zhengzhou、中国
        • 招聘中
        • Henan Cancer Hospital
        • 首席研究员:
          • Keshu Zhou
        • 接触:
      • Zhengzhou、中国
        • 招聘中
        • The First Affiliated Hospital of Zhengzhou University
        • 接触:
        • 首席研究员:
          • Xudong Zhang
      • Ürümqi、中国
        • 招聘中
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • 首席研究员:
          • Yan Li
        • 接触:
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国
        • 招聘中
        • Fudan University Shanghai Cancer Center
        • 接触:
        • 首席研究员:
          • Fangfang Lv

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

其他名称:
  • 注射用盐酸吉西他滨
  • 利妥昔单抗注射液
  • 奥沙利铂注射液
安慰剂比较:The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

其他名称:
  • 注射用盐酸吉西他滨
  • 利妥昔单抗注射液
  • 奥沙利铂注射液

Patients will receive HMPL-760 placebo once daily (QD) orally.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS)
大体时间:Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
大体时间:Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
大体时间:Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
大体时间:Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
大体时间:Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
大体时间:Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

次要结果测量

结果测量
措施说明
大体时间
Independent review committee (IRC)-assessed PFS
大体时间:Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
大体时间:Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
大体时间:Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
大体时间:Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
大体时间:Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
大体时间:Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
大体时间:Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
大体时间:At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

其他结果措施

结果测量
措施说明
大体时间
Biomarker assessment
大体时间:Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
大体时间:Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Weili Zhao、Ruijin Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月20日

初级完成 (估计的)

2028年4月30日

研究完成 (估计的)

2028年12月30日

研究注册日期

首次提交

2026年1月28日

首先提交符合 QC 标准的

2026年2月6日

首次发布 (实际的)

2026年2月13日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅